BCG instillation for medium- to high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old and expected to live at least 2 more years.
- Your bladder cancer must be a type called non-muscle invasive urothelial carcinoma and it must test positive for PD-L1.
- You must be in fairly good health, with a performance status score of 0–2 (able to do daily activities, may need some help).
- You cannot have other cancers, active infections, severe heart or kidney disease, or be pregnant or breastfeeding.
- You must be willing to complete screening tests (blood work, imaging, and a biopsy) and possibly a second surgery to confirm eligibility.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.